Regulation And Legal
Viatris Sues Novo Nordisk Over Wegovy Patent
Viatris, via Mylan, sued in Delaware federal court to declare its planned generic Wegovy does not infringe Novo Nordisk’s single‑dose pen patent.
Novo Nordisk generated nearly $31 billion from its sem
